1. Signaling Pathways
  2. Apoptosis
  3. TNF Receptor
  4. TNFRSF3/CD18 Isoform

TNFRSF3/CD18

TNFRSF3/CD18, also known as LTβR, is a lymphotoxin-β-specific TNF receptor that supports cell-surface lymphotoxin biology distinct from secreted LTα[1]. Mechanistically, LTβR activates classical and alternative NF-κB signaling, including NF-κB2/p100 processing to p52 through NIK and IKKα[2]. In immune tissue models, LTβR deficiency disrupts Peyer’s patches, lymph nodes, follicular dendritic cell networks, and affinity maturation in peripheral lymphoid tissues[3][4]. Compared with soluble LTα signaling, LTβR primarily interprets membrane LTα1β2 and LIGHT/TNFSF14 inputs, linking stromal-cell signaling to lymphoid organogenesis and inflammatory microarchitecture[1][3][4]. For experimental applications, soluble LTβR-Ig suppresses LTβR-dependent follicular dendritic cell markers and germinal-center activity, while LIGHT-driven LTβR activation can mediate tumor-cell apoptosis in defined models[5][6].

TNFRSF3/CD18 Related Products (1):

Cat. No. Product Name Effect Purity
  • HY-P991635
    PF-07329640
    Antagonist
    PF-07329640 is a humanized monoclonal antibody inhibitor targeting TNFRSF3. PF-07329640 can be used for advanced/metastatic solid tumors like non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) research.